by Unfractionated Heparin Market: Snapshot
The global unfractionated heparin market is set to collect handsome revenues during the forecast period of 2019 to 2027. This growth is attributed to plethora of factors. Unfractionated heparin is a naturally occurring anticoagulant. Owing to its ability to prevent blood clots, unfractionated heparin is widely used in heart lung and dialysis machines. At the same time, it is effective for treating blood clotting disorder such as pulmonary embolism and deep venous thrombosis. All these applications suggest that the global unfractionated heparin market will witness stupendous demand avenues in the forthcoming years.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111880
Unfractionated heparin is gaining traction owing to plethora of features it holds. It is widely accepted due to its instantaneous onset of action, uncomplicated laboratory monitoring, short half-life, and ability to get reversed (protamine). Apart from this, it is cost efficient. Unfractionated heparin is also used for treating venous thromboembolism (VTE) including pulmonary embolism (PE) and deep vein thrombosis (DVT). This factor is stimulating the growth of the global unfractionated heparin market.
In recent years, there is considerable increase in number of surgical procedures. This factor is working as a driver for global unfractionated heparin market. Vendors working in the market for unfractionated heparin hold phenomenal avenues for growth during forthcoming years. One of the key reasons for this growth is the patent expiration for major unfractionated heparin.
On regional front, the unfractionated heparin market is expected to gain lucrative avenues in Europe. Key reason for this growth is considerable growth in the number of research activities and increased cases of diseases in the region. In addition to this, the market for unfractionated heparin is expected to grow at swift speed in Asia Pacific. Key factors supporting the growth of the unfractionated heparin market are increase in older population, improved initiative by government bodies to advance the healthcare sector, and presence of major players in the region.
This report analyzes the current scenario and future prospects of the global unfractionated heparin market. Unfractionated heparin is a naturally occurring anticoagulant that is primarily in dialysis and heart lung machines to prevent blood clots as well as for the treatment of blood clotting disorder like deep venous thrombosis and pulmonary embolism. Due to its immediate onset of action, short half-life, simple laboratory monitoring, ability to get reversed (protamine), and low cost have led to its wide adoption.
Increase in use of unfractionated heparin for the treatment of venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE) along with increasing number of surgical procedures are the major drivers for global unfractionated heparin market. Although unfractionated heparin is one of the most primitive forms of heparin, the narrow therapeutic window and risk associated with bleeding act as the major restraints to its market across the globe.
Patent expiration for majority of unfractionated heparin have already created a huge latent opportunity for generic and biosimilar manufacturers in the forthcoming years. This will have positive impact on the market.
According to the World Health Organization (WHO), prolonged travelling by passengers via any automobile, train, or airplane for more than four hours increases the risk of developing venous thromboembolism. Coagulation disorders such as venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, affect approximately 1 million people in the U.S. every year. According to the Centers for Disease Control and Prevention approximately 500,000 to 900,000 people in the U.S. are affected by VTE every year. A study published by Deutsches Arzteblatt International in 2013 revealed that the annual incidence rate of diagnosed VTE in Germany stood at 150 to 200 cases per 100,000. The statistics above clearly indicate the demand for safe, reliable, and affordable anticoagulants. Simultaneously which is expected to drive global unfractionated heparin market.
The report provides an elaborate executive summary, which includes a snapshot of various segments of the global unfractionated heparin market. It also provides information and data analysis of the global unfractionated heparin market with regards to segments based on source and distribution channel, and region.
The overview section of the unfractionated heparin market report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global unfractionated heparin market
The report includes company profiles that provide information about their business, product portfolios, and competitive landscape in the global unfractionated heparin market
The report on the global unfractionated heparin market also offers market attractiveness analysis of regions and segments
The last section of the global unfractionated heparin market report comprises quantitative and qualitative analysis on market share/position of key players operating in the global unfractionated heparin market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global unfractionated heparin market.
Market size of the global unfractionated heparin market and forecast for each of the segments have been provided from 2017 to 2027. The CAGRs of respective segments have also been provided from 2019 to 2027, considering 2018 as the base year.
Global: Regional Outlook
In terms of region, the global unfractionated heparin market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and Rest of Middle East & Africa). Each region considered in the market has been further divided into countries/sub-regions.
The unfractionated heparin market report provides size and forecast for each region and country/sub-region from 2017 to 2027. The CAGR for each of these regions and countries has also been provided for the forecast period from 2019 to 2027. The unfractionated heparin market study also covers the competitive scenario in these regions.
Companies Covered in Global Unfractionated heparin market Report
Key players in the global unfractionated heparin market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies.
Major players having presence in the global unfractioned heparin market include
- Becton
- Dickinson and Company
- bioMérieux S.A.
- Bio-Rad Laboratories, Inc
- Eiken Chemical Co, Ltd.
- EMD (Merck) Millipore
- Hi-Media Laboratories Pvt. Ltd.
- Neogen Corporation
- Sigma-Aldrich Co. LLC
- Scharlab S.L.
- Thermo Fisher Scientific,
Key Questions Answered in Global Unfractionated Heparin Market Report
- What are the major drivers, restraints, and opportunities in the global unfractionated heparin market?
- What are the revenue share projections of key segments of the global unfractionated heparin market during the forecast period?
- Which segment is likely to lead the global unfractionated heparin market in terms of revenue by 2027?
- How mergers & acquisitions among players are widening the scope for the market?
- What is the market position of different companies operating in the global unfractionated heparin market?
Global Unfractionated Heparin Market – Segmentation
Source
- Bovine
- Porcine
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111880/2900
